BACKGROUND: In the United States, black individuals infected with human immunodeficiency virus (HIV) have higher rates of virologic failure on antiretroviral therapy (ART) and of death compared to white individuals. The cause for these disparities is uncertain. We sought to examine differences in virologic outcomes among antiretroviral-naive clinical trial participants starting randomized ART and to investigate factors to explain the differences. METHODS: Individual-level data from participants initiating ART in 5 AIDS Clinical Trials Group studies were analyzed. Included studies were those conducted during 1998-2006 with a primary outcome of virologic failure. The primary outcome measure was time to virologic failure, regardless of ART changes. RESULTS:A total of 2495 individuals (1151 black; 1344 white) were included with a median follow-up of 129 weeks. Compared to whites, blacks had an increased hazard of virologic failure (hazard ratio [HR]; 1.7; 95% confidence interval [CI], 1.4-1.9; P < .001), with no evidence of heterogeneity across regimens (P = .97); the association remained after adjustment for measured confounders (HR, 1.4; 95% CI, 1.2-1.6; P < .001). Increased hazard of virologic failure was associated with younger age, higher pretreatment HIV type 1 RNA level, lower pretreatment CD4 cell count, hepatitis C antibody, less education, and recent nonadherence to treatment. Sensitivity analyses with different endpoint definitions demonstrated similar results. CONCLUSIONS: In this analysis, blacks had a 40% higher virologic failure risk than whites that was not explained by measured confounders. The observation was consistent over a range of regimens, suggesting that the difference may be driven by social factors; however, biological factors cannot be ruled out. Further research should identify the sources of racial disparities and develop strategies to reduce them.
RCT Entities:
BACKGROUND: In the United States, black individuals infected with human immunodeficiency virus (HIV) have higher rates of virologic failure on antiretroviral therapy (ART) and of death compared to white individuals. The cause for these disparities is uncertain. We sought to examine differences in virologic outcomes among antiretroviral-naive clinical trial participants starting randomized ART and to investigate factors to explain the differences. METHODS: Individual-level data from participants initiating ART in 5 AIDS Clinical Trials Group studies were analyzed. Included studies were those conducted during 1998-2006 with a primary outcome of virologic failure. The primary outcome measure was time to virologic failure, regardless of ART changes. RESULTS: A total of 2495 individuals (1151 black; 1344 white) were included with a median follow-up of 129 weeks. Compared to whites, blacks had an increased hazard of virologic failure (hazard ratio [HR]; 1.7; 95% confidence interval [CI], 1.4-1.9; P < .001), with no evidence of heterogeneity across regimens (P = .97); the association remained after adjustment for measured confounders (HR, 1.4; 95% CI, 1.2-1.6; P < .001). Increased hazard of virologic failure was associated with younger age, higher pretreatment HIV type 1 RNA level, lower pretreatment CD4 cell count, hepatitis C antibody, less education, and recent nonadherence to treatment. Sensitivity analyses with different endpoint definitions demonstrated similar results. CONCLUSIONS: In this analysis, blacks had a 40% higher virologic failure risk than whites that was not explained by measured confounders. The observation was consistent over a range of regimens, suggesting that the difference may be driven by social factors; however, biological factors cannot be ruled out. Further research should identify the sources of racial disparities and develop strategies to reduce them.
Authors: Margaret A Fischl; Heather J Ribaudo; Ann C Collier; Alejo Erice; Marina Giuliano; Marjorie Dehlinger; Joseph J Eron; Michael S Saag; Scott M Hammer; Stefano Vella; Gene D Morse; Judith E Feinberg; Lisa M Demeter; Susan H Eshleman Journal: J Infect Dis Date: 2003-08-15 Impact factor: 5.226
Authors: Charles Flexner; Camlin Tierney; Robert Gross; Adriana Andrade; Christina Lalama; Susan H Eshleman; Judith Aberg; Ian Sanne; Teresa Parsons; Angela Kashuba; Susan L Rosenkranz; Anne Kmack; Elaine Ferguson; Marjorie Dehlinger; Donna Mildvan Journal: Clin Infect Dis Date: 2010-04-01 Impact factor: 9.079
Authors: Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: Robert W Shafer; Laura M Smeaton; Gregory K Robbins; Victor De Gruttola; Sally W Snyder; Richard T D'Aquila; Victoria A Johnson; Gene D Morse; Mostafa A Nokta; Ana I Martinez; Barbara M Gripshover; Pamposh Kaul; Richard Haubrich; Mary Swingle; S Debra McCarty; Stefano Vella; Martin S Hirsch; Thomas C Merigan Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Cynthia A Kleeberger; Jennifer Buechner; Frank Palella; Roger Detels; Sharon Riddler; Rebecca Godfrey; Lisa P Jacobson Journal: AIDS Date: 2004-03-05 Impact factor: 4.177
Authors: Linda Beer; Heather Bradley; Christine L Mattson; Christopher H Johnson; Brooke Hoots; Roy L Shouse Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: Cindy J Bednasz; Charles S Venuto; Qing Ma; Eric S Daar; Paul E Sax; Margaret A Fischl; Ann C Collier; Kimberly Y Smith; Camlin Tierney; Yang Yang; Gregory E Wilding; Gene D Morse Journal: Ther Drug Monit Date: 2017-12 Impact factor: 3.681
Authors: Lauren Lipira; Emily C Williams; David Huh; Christopher G Kemp; Paul E Nevin; Preston Greene; Joseph M Unger; Patrick Heagerty; Audrey L French; Susan E Cohn; Janet M Turan; Michael J Mugavero; Jane M Simoni; Michele P Andrasik; Deepa Rao Journal: AIDS Behav Date: 2019-08
Authors: Jyoti S Mathad; Nikhil Gupte; Ashwin Balagopal; David Asmuth; James Hakim; Breno Santos; Cynthia Riviere; Mina Hosseinipour; Patcharaphan Sugandhavesa; Rosa Infante; Sandy Pillay; Sandra W Cardoso; Noluthando Mwelase; Jyoti Pawar; Sima Berendes; Nagalingeswaran Kumarasamy; Bruno B Andrade; Thomas B Campbell; Judith S Currier; Susan E Cohn; Amita Gupta Journal: J Acquir Immune Defic Syndr Date: 2016-10-01 Impact factor: 3.731
Authors: Chanelle J Howe; Akilah Dulin-Keita; Stephen R Cole; Joseph W Hogan; Bryan Lau; Richard D Moore; W Christopher Mathews; Heidi M Crane; Daniel R Drozd; Elvin Geng; Stephen L Boswell; Sonia Napravnik; Joseph J Eron; Michael J Mugavero Journal: Am J Epidemiol Date: 2018-02-01 Impact factor: 5.363